Early analysis suggests that another mRNA vaccine is safe, but its effectiveness isn’t yet known.

Early analysis suggests that another mRNA vaccine is safe, but its effectiveness isn’t yet known.

The New York Times-Science·2021-05-29 17:02

The German company CureVac said on Friday that its Covid-19 vaccine had passed its first interim analysis, but that it was not yet ready to share data on how well it protects against infection. The shot could be cheaper and more accessible to low-income countries that lack vaccines.

……

Read full article on The New York Times-Science

Health News